[11-7]PBPK Modeling to Simulate and Predict Xenobiotic Disposition and Drug Interactions

报告题目：PBPK Modeling to Simulate and Predict Xenobiotic Disposition and Drug Interactions
报 告 人：赵远胜 博士（The Hamner Institutes for Health Sciences, Center for Human Health Assessment）
报告时间：2014年11月7日（星期五）上午9:00
报告地点：独墅湖校区二期云轩楼2301室

报告摘要：
Physiologically-based pharmacokinetic (PBPK) modeling, treating the body as anatomical compartments, utilizes physiological and chemical-specific parameters, as well as mathematical equations to quantitatively describe the in vivo disposition of xenobiotics. PBPK models can be extrapolated across dose levels, formulations, routes of administration, and species. This modeling approach may also allow for evaluating the effects of intrinsic (e.g., genetics, organ dysfunction, age) and extrinsic (e.g., drug-drug interactions) factors, alone or in combinations, on drug exposure. In this presentation, three examples of PBPK modeling will be presented. The first example is the development of PBPK models for an anti-tumor agent in animal species and the model extrapolation from animals to humans. In the second example, PBPK models were combined with ‘in vivo [I]/Ki’ to predict drug-drug interactions involving P-glycoprotein. In the last example, a PBPK model was constructed to describe the disposition of nano-sized cadmium oxide in mice during pregnancy. This model was subsequently used to interpret the impact of cadmium oxide nanoparticles on the fetal development. These examples demonstrate the applications of PBPK modeling in pharmaceutical research and in toxicology.

报告人简介：
Dr. Yuansheng Zhao received his Ph.D. degree in Pharmacokinetics from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in 2010. Afterwards, he worked as a research scientist at Hutchison Medipharma, where he was mainly responsible for in vivo pharmacokinetic studies of drug candidates for investigational new drug applications. In Oct 2011, he began working as a postdoctoral fellow at Mount Sinai School of Medicine, where his research focused on mass spectrometry imaging and pharmacokinetic-pharmacodynamic modeling.
Dr. Zhao is currently a postdoctoral fellow at The Hamner Institutes for Health Sciences. His research interest is in the application of physiologically-based pharmacokinetic (PBPK) models to investigate the disposition of xenobiotics and to predict drug-drug interactions (DDIs). He has developed PBPK models for several engineered nanoparticles with different physicochemical properties, including nano-sized cadmium oxide, silver, and fullerenes, based on the biological fate of these nanoparticles in animal species. Extrapolation of these PBPK models from animals to humans is currently being conducted to support the assessment of human health risks from exposure to these nanomaterials. In addition, he combined PBPK model and ‘in vivo [I]/Ki’ to predict P-glycoprotein mediated DDIs in humans.